Compare American Homes 4 Rent Class A (AMH) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Homes 4 Rent Class A vs Danaher Corporation — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Danaher Corporation trades at $199.08 (market cap $140.88B). The key difference: Danaher Corporation is far larger — about 11.8× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| AMH | DHR | |
|---|---|---|
Market Cap | $11.97B | $140.88B |
Sector | Real Estate | Health |
52-Week High | $36.74 | $242.05 |
52-Week Low | $27.38 | $161.91 |
Enterprise Value | $17.05B | $153.66B |
Dividend Yield | 3.97% | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
Danaher (DHR) trades at $199.05, up 1.57% today, with strong technical momentum as price approaches resistance at $200. The company demonstrates consistent earnings beats with Q1 2026 EPS of $2.06 exceeding expectations of $1.94, though revenue growth remains modest at 2.9% year-over-year. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment, supporting positive analyst sentiment.
DHR presents a mixed outlook with strong analyst support (69% buy ratings) and a $214.73 consensus target offering 7.9% upside, but faces risks from elevated valuation (P/E 38.58) and slowing profit margins. The stock's near-term direction will depend on Q2 2026 earnings delivery and biotechnology segment performance amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
